Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: Implications for the etiology of thrombocytopenia

Blood

Volumn 101, Issue 1, 2003, Pages 58-63

  Seiffert, Dietmar ^a,b   Stern, Andrew M ^a,b   Ebling, William ^a,b   Rossi, Richard J ^a,b   Chen Barrett, Yu ^a,b   Wynn, Richard ^a,b   Hollis, Gregory F ^a,b   He, Bokang ^a,b   Kieras, Cathy J ^a,b   Pedicord, Donna L ^a,b   Cromley, Debra A ^a,b   Hua, Tsushung A ^a,b   Stein, Robert B ^a,b   Daly, Robert N ^a,b   Sferruzza, Anthony ^a,b   Pieniaszek, Henry J ^a,b   Billheimer, Jeffrey T ^a,b  

^a BRISTOL MYERS SQUIBB   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; DRUG DEPENDENT ANTIBODY; FIBRINOGEN RECEPTOR ANTAGONIST; ROXIFIBAN; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DEPENDENT ANTIBODY TESTING; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0037222079     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0471     Document Type: Article

References (19)

1. Berkowitz SD, Sane DC, Sigmon KN, et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J Am Coll Cardiol. 1998;32:311-319.
2. McClure MW, Berkowitz SD, Sparapani R, et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. Circulation. 1999;99:2892-2900.
3. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet. 1997;349:1429-1435.
4. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization: The EPILOG Investigators. N Engl J Med. 1997;336:1689-1696.
5. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: The EPISTENT Investigators: Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet. 1998;352:87-92.
6. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 (abciximab) administration. Circulation. 1997;95:809-813.
7. Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP. Abciximab-associated profound thrombocytopenia: Therapy with immunoglobulin and platelet transfusion. Am J Cardiol. 1996;78:1161-1166.
8. Tcheng JE, Kereiakes DJ, Lincoff AM, et al. Abciximab readministration: Results of the ReoPro Readministration Registry. Circulation. 2001;104:870-875.
9. Hongo RH, Brent BN. Association of eptifibatide and acute profound thrombocytopenia. Am J Cardiol. 2001;88:428-431.
10. Giugliano RP, McCabe CH, Sequeira RF, et al. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitory (RPR 109891) in patients with recent acute coronary syndromes: Results of the TIMI 15A and 15B trials. Am Heart J. 2000;140:81-93.
11. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial: The SYMPHONY Investigators: Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes. Lancet. 2000;355:337-345.
12. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/IIIa inhibition by orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000;102:149-156.
13. Billheimer JT, Dicker IB, Wynn R, et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood. 2002;99:3540-3546.
14. Bednar B, Cook JJ, Holahan MA, et al. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood. 1999;94:587-599.
15. Shattil SJ, Brass LF, Bennett JS, Pandhi P. Biochemical and functional consequences of dissociation of the platelet membrane glycoprotein IIb-IIIa complex. Blood. 1985;66:92-98.
16. Ginsberg MH, Loftus JC, Plow EF. Cytoadhesins, integrins, and platelets. Thromb Haemost. 1988;59:1-6.
17. Kieffer N, Phillips DR. Platelet membrane glycoproteins: Functions in cellular interaction. Annu Rev Cell Biol. 1990;6:329-357.
18. Khaspekova SG, Vlasik TN, Byzova TV, Vinogradov DV, Berndt MC, Mazurov AV. Detection of an epitope specific for the dissociated form of glycoprotein IIIa of platelet membrane glycoprotein IIb-IIIa complex and its expression on the surface of adherent platelets. Br J Haematol. 1993;85:332-340.
19. Olson RE, Sielecki TM, Wityak J, et al. Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action. J Med Chem. 1999;42:1178-1192.